Home » Stock Quotes » BME:ALM

Almirall SA BME:ALM

Today's live share price, quote history, chart & news

Price:
10.80 EUR
Change:
+0.11 (1.03%)
Price open 10.70
Previous close 10.69
Market cap 1.88B
Volume 205.60K
Day high 10.98
Day low 10.69
Year high 18.50
Year low 8.81

About Almirall SA

Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, acne, rosacea, and psoriasis; and central nervous system, cardiovascular, and gastrointestinal diseases. Its strategic brands include ACTIKERALL, BALNEUM, DECODERM, SATIVEX, SKILARENCE, and DECODERM. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases, as well as drug discovery partnership with X-Chem, Inc.; and a research collaboration with Iktos in the area of artificial intelligence for new drug design. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Latest Almirall SA news

18th March 2015
AstraZeneca share price up as respiratory drug succeeds in late-stage trials
5th February 2015
AstraZeneca share price opens lower as Q4 results disappoint
3rd November 2014
AstraZeneca share price: Drugmaker wraps up respiratory franchise deal
30th July 2014
AstraZeneca share price: Respiratory portfolio boosted with $2bn deal
Overview
Name Almirall SA
Exchange Madrid Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Country Spain
Full time employees 1,773

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.